

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/000562

International filing date: 18 January 2005 (18.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: EP
Number: 04100203.1
Filing date: 22 January 2004 (22.01.2004)

Date of receipt at the International Bureau: 24 February 2005 (24.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

04100203.1

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
.p.o.

R C van Dijk



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

PCT/EP2005/000562

18.01.05

Anmeldung Nr:
Application no.: 04100203.1
Demande no:

Anmeldetag:
Date of filing: 22.01.04
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Akzo Nobel N.V.
Velperweg 76
6824 BM Arnhem
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

LAWSONIA INTRACELLULARIS 75 kD SUBUNIT VACCINE

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07K14/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

Lawsonia intracellularis 75 kD subunit vaccine.

The present invention relates i.a. to nucleic acids encoding novel *Lawsonia intracellularis* proteins, to DNA fragments, recombinant DNA molecules and live
5 recombinant carriers comprising these sequences, to host cells comprising such nucleic acids, DNA fragments, recombinant DNA molecules and live recombinant carriers, to proteins encoded by these nucleotide sequences and to their use for the manufacturing of vaccines, to vaccines for combating *Lawsonia intracellularis* infections and methods for the preparation thereof and to diagnostic tests for the detection of *Lawsonia*
10 *intracellularis* antigens and for the detection of antibodies against *Lawsonia intracellularis*.

Porcine proliferative enteropathy (PPE or PE) has become an important disease of the modern pig industry world-wide. The disease affects 15% to 50% of the growing herds
15 and up to 30% of the individual animals in established problem herds. Today annual economical losses have been estimated US\$ 5-10 in extra feed and facility time costs per affected pig. PPE is a group of chronic and acute conditions of widely differing clinical signs (death, pale and anaemic animals, watery, dark or bright red diarrhoea, depression, reduced appetite and reluctance to move, retarded growth and increased FCR). However
20 there are two consistent features. The first, a pathological change only visible at necropsy, is a thickening of the small intestine and colon mucosa. The second is the occurrence of intracytoplasmatic small-curved bacteria in the enterocytes of the affected intestine. These bacteria have now been established as the etiological agent of PPE and have been name *Lawsonia intracellularis*.

25 Over the years *Lawsonia intracellularis* has been found to affect a large group of animals including monkeys, rabbits, ferrets, hamsters, fox, horses, and other animals as diverse as ostrich and emoe. *Lawsonia intracellularis* is a gram-negative, flagellated bacterium that multiplies in eukaryotic enterocytes only and no cell-free culture has been described. In
30 order to persist and multiply in the cell *Lawsonia intracellularis* must penetrate dividing crypt cells. The bacterium associates with the cell membrane and quickly enters the

enterocyte via an entry vacuole. This then rapidly breaks down (within 3 hours) and the bacteria flourish and multiply freely in the cytoplasm. The mechanisms by which the bacteria cause infected cells to fail to mature, continue to undergo mitosis and form hypoplastic crypt cells is not yet understood.

5

The current understanding of *Lawsonia intracellularis* infection, treatment and control of the disease has been hampered by the fact that *Lawsonia intracellularis* can not be cultivated in cell-free media. Although there are reports of successful co-culturing *Lawsonia intracellularis* in rat enterocytes this has not lead to the development of inactivated vaccines for combating *Lawsonia intracellularis*, although there clearly is a need for such vaccines.

10

It is an objective of the present invention to provide a vaccine for combating *Lawsonia intracellularis* infection.

15

It was surprisingly found now, that *Lawsonia intracellularis* produces a novel protein that is capable of inducing protective immunity against *Lawsonia intracellularis*.

The novel protein will be referred to as the 75 kD protein.

20

The amino acid sequence of the novel protein is presented in sequence identifier SEQ ID NO: 2. The gene encoding this protein has been sequenced and its nucleic acid sequence is shown in sequence identifier SEQ ID NO: 1. The gene will also be referred to in the Examples as "gene 5074".

25

It is well-known in the art, that many different nucleic acid sequences can encode one and the same protein. This phenomenon is commonly known as wobble in the second and especially the third base of each triplet encoding an amino acid. This phenomenon can result in a heterology of about 30% for two nucleic acid sequences still encoding the same protein. Therefore, two nucleic acid sequences having a sequence homology of

30

about 70 % can still encode one and the same protein.

Thus, one embodiment relates to nucleic acids encoding a *Lawsonia intracellularis* protein and to parts of that nucleic acid that encode an immunogenic fragment of that protein, wherein those nucleic acids or parts thereof have a level of homology with the nucleic acid of which the sequence is given in SEQ ID NO: 1 of at least 90 %.

5

Preferably, the nucleic acid encoding this *Lawsonia intracellularis* protein or the part of said nucleic acid has at least 92 %, preferably 94 %, more preferably 95 % and even more preferably 96% homology with the nucleic acid having the sequence given in SEQ ID NO: 1. Even more preferred is a homology level of 98 % or even 100 %.

10

The level of nucleotide homology can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTN" that can be found at www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html.

A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS Microbiol. Letters 174: 247-250 (1999). Parameters used are the default parameters: Reward for a match: +1. Penalty for a mismatch: -2. Open gap: 5. Extension gap: 2. Gap x_dropoff: 50.

Another approach for deciding if a certain nucleic acid is or is not a nucleic acid according to the invention relates to the question if that certain nucleic acid does hybridise under stringent conditions to nucleic acids having the nucleotide sequence as depicted in SEQ ID NO: 1.

If a nucleic acid hybridises under stringent conditions to the nucleotide sequence as depicted in SEQ ID NO: 1, it is considered to be a nucleic acid according to the invention.

25

The definition of stringent conditions follows from the formula of Meinkoth and Wahl (1984. Hybridization of nucleic acids immobilized on solid supports. Anal. Biochem. 138: 267-284.)

$T_m = [81.5^{\circ}\text{C} + 16.6(\log M) + 0.41(\%GC) - 0.61(\%\text{formamide}) - 500/L] - 1^{\circ}\text{C}/1\%\text{mismatch}$

30

In this formula, M is molarity of monovalent cations; %GC is the percentage of guanosine and cytosine nucleotides in the DNA; L is the length of the hybrid in base pairs.

5

Stringent conditions are those conditions under which nucleic acids or fragments thereof still hybridise, if they have a mismatch of 10% at the most, to the nucleic acid having the sequence depicted in SEQ ID NO: 1.

- 10 Since the present invention discloses nucleic acids encoding novel *Lawsonia intracellularis* proteins, it is now for the first time possible to obtain these proteins in sufficient quantities. This can e.g. be done by using expression systems to express the genes encoding the proteins.

- Therefore, in a more preferred embodiment, the invention relates to DNA fragments
15 comprising a nucleic acid according to the invention. Such DNA fragments can e.g. be plasmids, into which a nucleic acid according to the invention is cloned. Such DNA fragments are e.g. useful for enhancing the amount of DNA for use as a primer, as described below.

- 20 An essential requirement for the expression of the nucleic acid is an adequate promoter functionally linked to the nucleic acid, so that the nucleic acid is under the control of the promoter. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells used as host cells for protein expression.

- 25 Therefore, an even more preferred form of this embodiment relates to a recombinant DNA molecule comprising a DNA fragment or a nucleic acid according to the invention that is placed under the control of a functionally linked promoter. This can be accomplished by means of e.g. standard molecular biology techniques. (Sambrook, J. and Russell, D.W., Molecular cloning: a laboratory manual, 2001. ISBN 0-87969-577-3).

- 30 Functionally linked promoters are promoters that are capable of controlling the transcription of the nucleic acids to which they are linked.

Such a promoter can be a Lawsonia promoter e.g. the promoter involved in *in vivo* expression of the gene encoding the 75 kD protein, provided that that promoter is functional in the cell used for expression. It can also be a heterologous promoter. When the host cells are bacteria, useful expression control sequences which may be used

5 include the Trp promoter and operator (Goeddel, et al., Nucl. Acids Res., 8, 4057, 1980); the lac promoter and operator (Chang, et al., Nature, 275, 615, 1978); the outer membrane protein promoter (Nakamura, K. and Inouge, M., EMBO J., 1, 771-775, 1982); the bacteriophage lambda promoters and operators (Remaut, E. et al., Nucl. Acids Res., 11, 4677-4688, 1983); the α -amylase (*B. subtilis*) promoter and operator,

10 termination sequences and other expression enhancement and control sequences compatible with the selected host cell.

When the host cell is yeast, useful expression control sequences include, e.g., α -mating factor. For insect cells the polyhedrin or p10 promoters of baculoviruses can be used (Smith, G.E. et al., Mol. Cell. Biol. 3, 2156-65, 1983). When the host cell is of

15 mammalian origin illustrative useful expression control sequences include the SV-40 promoter (Berman, P.W. et al., Science, 222, 524-527, 1983) or the metallothionein promoter (Brinster, R.L., Nature, 296, 39-42, 1982) or a heat shock promoter (Voellmy et al., Proc. Natl. Acad. Sci. USA, 82, 4949-53, 1985).

20 Bacterial, yeast, fungal, insect and mammalian cell expression systems are very frequently used systems. Such systems are well-known in the art and generally available, e.g. commercially through Invitrogen (www.invitrogen.com), Novagen (www.merckbiosciences.de) or Clontech Laboratories, Inc. 4030 Fabian Way, Palo Alto, California 94303-4607, USA. Next to these expression systems, parasite-based

25 expression systems are very attractive expression systems. Such systems are e.g. described in the French Patent Application with Publication number 2 714 074, and in US NTIS Publication No US 08/043109 (Hoffman, S. and Rogers, W.: Public. Date 1 December 1993).

30 A still even more preferred form of this embodiment of the invention relates to Live Recombinant Carriers (LRCs) comprising a nucleic acid encoding the 75 kD protein or

an immunogenic fragment thereof according to the invention, a DNA fragment according to the invention or a recombinant DNA molecule according to the invention. Such carriers are e.g. bacteria and viruses. These LRCs are micro-organisms or viruses in which additional genetic information, in this case a nucleic acid encoding the 75 kD protein or an immunogenic fragment thereof according to the invention has been cloned. Animals infected with such LRCs will produce an immunogenic response not only against the immunogens of the carrier, but also against the immunogenic parts of the protein(s) for which the genetic code is additionally cloned into the LRC, e.g. the 75 kD protein.

10 As an example of bacterial LRCs, attenuated Salmonella strains known in the art can attractively be used.

Live recombinant carrier parasites have i.a. been described by Vermeulen, A. N. (Int. Journ. Parasitol. 28: 1121-1130 (1998))

Also, LRC viruses may be used as a way of transporting the nucleic acid into a target cell. Live recombinant carrier viruses are also called vector viruses. Viruses often used as vectors are Vaccinia viruses (Panicali et al; Proc. Natl. Acad. Sci. USA, 79: 4927 (1982), Herpesviruses (E.P.A. 0473210A2), and Retroviruses (Valerio, D. et al; in Baum, S.J., Dicke, K.A., Lotzova, E. and Pluznik, D.H. (Eds.), Experimental Haematology today - 1988. Springer Verlag, New York: pp. 92-99 (1989)).

20

The technique of *in vivo* homologous recombination, well-known in the art, can be used to introduce a recombinant nucleic acid into the genome of a bacterium, parasite or virus of choice, capable of inducing expression of the inserted nucleic acid according to the invention in the host animal.

25

Finally another form of this embodiment of the invention relates to a host cell comprising a nucleic acid encoding a protein according to the invention, a DNA fragment comprising such a nucleic acid or a recombinant DNA molecule comprising such a nucleic acid under the control of a functionally linked promoter. This form also relates to a host cell containing a live recombinant carrier containing a nucleic acid molecule encoding a 75 kD protein or a fragment thereof according to the invention.

30

A host cell may be a cell of bacterial origin, e.g. *Escherichia coli*, *Bacillus subtilis* and *Lactobacillus* species, in combination with bacteria-based plasmids as pBR322, or bacterial expression vectors as pGEX, or with bacteriophages. The host cell may also be of eukaryotic origin, e.g. yeast-cells in combination with yeast-specific vector molecules, or higher eukaryotic cells like insect cells (Luckow et al; Bio-technology 6: 47-55 (1988)) in combination with vectors or recombinant baculoviruses, plant cells in combination with e.g. Ti-plasmid based vectors or plant viral vectors (Barton, K.A. et al; Cell 32: 1033 (1983), mammalian cells like Hela cells, Chinese Hamster Ovary cells (CHO) or Crandell Feline Kidney-cells, also with appropriate vectors or recombinant viruses.

Another embodiment of the invention relates to the novel proteins and to immunogenic fragments thereof according to the invention.

15 The concept of immunogenic fragments will be defined below.

One form of this embodiment relates i.a. to *Lawsonia intracellularis* proteins that have an amino acid sequence that is at least 90 % homologous to the amino acid sequence as depicted in SEQ ID NO: 2 and to immunogenic fragments of said protein.

20

In a preferred form, the embodiment relates to such *Lawsonia intracellularis* proteins that have a sequence homology of at least 92 %, preferably 94 %, more preferably 96 % homology to the amino acid sequence as depicted in SEQ ID NO: 2 and to immunogenic fragments of such proteins.

25 Even more preferred is a homology level of 98 % or even 100 %.

The level of protein homology can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTP", that can be found at www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html.

A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS Microbiol. Letters 174: 247-250 (1999). Matrix used: "blosum62". Parameters used are the default parameters:

Open gap: 11. Extension gap: 1. Gap x_dropoff: 50.

5

It will be understood that, for the particular proteins embraced herein, natural variations can exist between individual *Lawsonia intracellularis* strains. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence.

- 10 Amino acid substitutions which do not essentially alter biological and immunological activities, have been described, e.g. by Neurath et al in "The Proteins" Academic Press New York (1979). Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Other
- 15 amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile, Leu/Val and Ala/Glu. Based on this information, Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science, 227, 1435-1441, 1985) and determining the functional similarity between
- 20 homologous proteins. Such amino acid substitutions of the exemplary embodiments of this invention, as well as variations having deletions and/or insertions are within the scope of the invention as long as the resulting proteins retain their immune reactivity. This explains why *Lawsonia intracellularis* proteins according to the invention, when isolated from different field isolates, may have homology levels of about 90 %, while still
- 25 representing the same protein with the same immunological characteristics. Those variations in the amino acid sequence of a certain protein according to the invention that still provide a protein capable of inducing an immune response against infection with *Lawsonia intracellularis* or at least against the clinical manifestations of the infection are considered as "not essentially influencing the immunogenicity".

30

When a protein is used for e.g. vaccination purposes or for raising antibodies, it is however not necessary to use the whole protein. It is also possible to use a fragment of that protein that is capable, as such or coupled to a carrier such as e.g. KLH, of inducing an immune response against that protein, a so-called immunogenic fragment. An

5 "immunogenic fragment" is understood to be a fragment of the full-length protein that still has retained its capability to induce an immune response in the host, i.e. comprises a B- or T-cell epitope. At this moment, a variety of techniques is available to easily identify DNA fragments encoding antigenic fragments (determinants). The method described by Geysen et al (Patent Application WO 84/03564, Patent Application WO 86/06487, US
10 Patent NR. 4,833,092, Proc. Natl Acad. Sci. 81: 3998-4002 (1984), J. Imm. Meth. 102, 259-274 (1987), the so-called PEPSCAN method is an easy to perform, quick and well-established method for the detection of epitopes; the immunologically important regions of the protein. The method is used world-wide and as such well-known to man skilled in the art. This (empirical) method is especially suitable for the detection of B-cell epitopes.
15 Also, given the sequence of the gene encoding any protein, computer algorithms are able to designate specific protein fragments as the immunologically important epitopes on the basis of their sequential and/or structural agreement with epitopes that are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78: 38248-3828 (1981)),
20 and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47: 45-148 (1987) and US Patent 4,554,101). T-cell epitopes can likewise be predicted from the sequence by computer with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-1062 (1987) and US Patent application NTIS US
07/005,885). A condensed overview is found in: Shan Lu on common principles: Tibtech
25 9: 238-242 (1991), Good et al on Malaria epitopes; Science 235: 1059-1062 (1987), Lu for a review; Vaccine 10: 3-7 (1992), Berzowsky for HIV-epitopes; The FASEB Journal 5:2412-2418 (1991).

Therefore, one form of still another embodiment of the invention relates to vaccines
30 capable of protecting pigs against *Lawsonia intracellularis* infection, that comprise a

protein or an immunogenic fragment thereof, according to the invention as described above together with a pharmaceutically acceptable carrier.

5 Still another embodiment of the present invention relates to the proteins according to the invention for use in a vaccine.

Still another embodiment relates to the use of a protein according to the invention for the manufacturing of a vaccine for combating *Lawsonia intracellularis* infections.

10 One way of making a vaccine according to the invention is by biochemical purification of the proteins or immunogenic fragments thereof according to the invention from bacteria obtained through mucosal scrapings taken from the infected intestine wall. This is however a very time-consuming way of making the vaccine.

15 It is therefore much more convenient to use the expression products of the genes encoding the proteins or immunogenic fragments thereof according to the invention in vaccines. The nucleic acid of the gene encoding the 75 kD protein is provided by the present invention.

20 Such vaccines based upon the expression products of these genes can easily be made by admixing a protein according to the invention or an immunogenic fragment thereof according to the invention with a pharmaceutically acceptable carrier as described below.

Alternatively, a vaccine according to the invention can comprise live recombinant
25 carriers as described above, capable of expressing the proteins according to the invention or immunogenic fragments thereof according to the invention. Such vaccines, e.g. based upon a *Salmonella* carrier or a viral carrier infecting the enteric epithelium, or e.g. the respiratory epithelium have the advantage over subunit vaccines that they better mimic the natural way of infection of *Lawsonia intracellularis*. Moreover, their self-propagation
30 is an advantage since only low amounts of the recombinant carrier are necessary for immunisation.

Vaccines described above all contribute to active vaccination, i.e. the host's immune system is triggered by a protein according to the invention or an immunogenic fragment thereof, to make antibodies against these proteins.

- 5 Alternatively, such antibodies can be raised in e.g. rabbits or can be obtained from antibody-producing cell lines as described below. Such antibodies can then be administered to the host animal. This method of vaccination, passive vaccination, is the vaccination of choice when an animal is already infected, and there is no time to allow the natural immune response to be triggered. It is also the preferred method for
- 10 vaccinating immune-compromised animals. Administered antibodies against *Lawsonia intracellularis* can in these cases bind directly to the bacteria. This has the advantage that it immediately decreases or stops *Lawsonia intracellularis* growth.
- Therefore, one other form of this embodiment of the invention relates to vaccines comprising antibodies against the 75 kD *Lawsonia intracellularis* protein according to
- 15 the invention.

Vaccines can also be based upon host cells as described above, that comprise the proteins or immunogenic fragments thereof according to the invention.

- 20 An alternative and efficient way of vaccination is direct vaccination with DNA encoding the relevant antigen. Direct vaccination with DNA encoding proteins has been successful for many different proteins. (As reviewed in e.g. Donnelly et al., The Immunologist 2: 20-26 (1993)).

This way of vaccination is very attractive for the vaccination of pigs against *Lawsonia intracellularis* infection.

25

Therefore, still other forms of this embodiment of the invention relate to vaccines comprising nucleic acids encoding a protein according to the invention or immunogenic fragments thereof according to the invention, and to vaccines comprising DNA fragments that comprise such nucleic acids.

- 30 Still other forms of this embodiment relate to vaccines comprising recombinant DNA molecules according to the invention.

DNA vaccines can easily be administered through intradermal application e.g. using a needle-less injector. This way of administration delivers the DNA directly into the cells of the animal to be vaccinated. Amounts of DNA in the microgram range between 1 and 100 µg provide very good results.

5

In a further embodiment, the vaccine according to the present invention additionally comprises one or more antigens derived from other pig pathogenic organisms and viruses, or genetic information encoding such antigens.

Such organisms and viruses are preferably selected from the group of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, *Escherichia coli*, *Erysipelothrix rhusiopathiae*, *Bordetella bronchiseptica*, *Salmonella choleraesuis*, *Haemophilus parasuis*, *Pasteurella multocida*, *Streptococcus suis*, *Mycoplasma hyopneumoniae*, *Brachyspira hyodysenteriae* and *Actinobacillus pleuropneumoniae*.

15

All vaccines according to the present invention comprise a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form the carrier can e.g. be a buffer.

Methods for the preparation of a vaccine comprise the admixing of a protein according to the invention, or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.

Vaccines according to the present invention may in a preferred presentation also contain an adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants are Freund's Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers, muramyl dipeptides, Quil A^(R), mineral oil e.g. Bayol^(R) or Markol^(R), vegetable oil, and Carbopol^(R) (a homopolymer), or Diluvac^(R) Forte.

The vaccine may also comprise a so-called "vehicle". A vehicle is a compound to which the polypeptide adheres, without being covalently bound to it. Often used vehicle

30

compounds are e.g. aluminium hydroxide, -phosphate or -oxide, silica, Kaolin, and Bentonite.

A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP 242.380)

- 5 In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, e.g. Span or Tween.

Often, the vaccine is mixed with stabilisers, e.g. to protect degradation-prone polypeptides from being degraded, to enhance the shelf-life of the vaccine, or to improve freeze-drying efficiency. Useful stabilisers are i.a. SPGA (Bovarnik et al; J. Bacteriology
10 59: 509 (1950)), carbohydrates e.g. sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein or degradation products thereof, and buffers, such as alkali metal phosphates.

In addition, the vaccine may be suspended in a physiologically acceptable diluent. It goes without saying, that other ways of adjuvating, adding vehicle compounds or
15 diluents, emulsifying or stabilising a polypeptide are also embodied in the present invention.

Vaccines according to the invention can very suitably be administered in amounts ranging between 1 and 100 micrograms, although smaller doses can in principle be used.
20 A dose exceeding 100 micrograms will, although immunologically very suitable, be less attractive for commercial reasons.

Vaccines based upon live attenuated recombinant carriers, such as the LRC-viruses and bacteria described above can be administered in much lower doses, because they multiply
25 themselves during the infection. Therefore, very suitable amounts would range between 10^3 and 10^9 CFU/PFU for respectively bacteria and viruses.

Many ways of administration can be applied. Oral application is a very attractive way of administration, because the infection is an infection of the digestive tract. A preferred
30 way of oral administration is the packaging of the vaccine in capsules, known and frequently used in the art, that only disintegrate after they have passed the highly acidic

environment of the stomach. Also, the vaccine could be mixed with compounds known in the art for temporarily enhancing the pH of the stomach.

Systemic application is also suitable, e.g. by intramuscular application of the vaccine. If this route is followed, standard procedures known in the art for systemic application are well-suited.

From a point of view of protection against disease, a quick and correct diagnosis of *Lawsonia intracellularis* infection is important.

Therefore it is another objective of this invention to provide diagnostic tools suitable for the detection of *Lawsonia intracellularis* infection.

A diagnostic test for the detection of *Lawsonia intracellularis* antibodies in sera can be e.g. a simple standard sandwich-ELISA-test in which 75 kD protein or antigenic fragments thereof according to the invention are coated to the wall of the wells of an ELISA-plate. A method for the detection of such antibodies is e.g. incubation of 75 kD protein or antigenic fragments thereof with serum from mammals to be tested, followed by e.g. incubation with a labelled antibody against the relevant mammalian antibody. A colour reaction can then reveal the presence or absence of antibodies against *Lawsonia intracellularis*. Another example of a diagnostic test system is e.g. the incubation of a Western blot comprising the 75 kD protein or an antigenic fragment thereof according to the invention, with serum of mammals to be tested, followed by analysis of the blot.

Thus, another embodiment of the present invention relates to diagnostic tests for the detection of antibodies against *Lawsonia intracellularis*. Such tests comprise a protein or a fragment thereof according to the invention.

A diagnostic test based upon the detection of antigenic material of the specific 75 kD protein of *Lawsonia intracellularis* antigens and therefore suitable for the detection of *Lawsonia intracellularis* infection can e.g. also be a standard ELISA test. In one example of such a test the walls of the wells of an ELISA plate are coated with antibodies directed against the 75 kD protein. After incubation with the material to be tested, labelled anti-

Lawsonia intracellularis antibodies are added to the wells. A colour reaction then reveals the presence of antigenic material from *Lawsonia intracellularis*.

Therefore, still another embodiment of the present invention relates to diagnostic tests for the detection of antigenic material of *Lawsonia intracellularis*. Such tests comprise
 5 antibodies against a protein or a fragment thereof according to the invention.

The polypeptides or immunogenic fragments thereof according to the invention expressed as characterised above can be used to produce antibodies, which may be polyclonal, monospecific or monoclonal (or derivatives thereof). If polyclonal antibodies are desired,
 10 techniques for producing and processing polyclonal sera are well-known in the art (e.g. Mayer and Walter, eds. *Immunochemical Methods in Cell and Molecular Biology*, Academic Press, London, 1987).

Monoclonal antibodies, reactive against the polypeptide according to the invention (or variants or fragments thereof) according to the present invention, can be prepared by
 15 immunising inbred mice by techniques also known in the art (Kohler and Milstein, *Nature*, 256, 495-497, 1975).

Methods for large-scale production of antibodies according to the invention are also known in the art. Such methods rely on the cloning of (fragments of) the genetic
 20 information encoding the protein according to the invention in a filamentous phage for phage display. Such techniques are described i.a. at the "Antibody Engineering Page" under "filamentous phage display" at <http://aximtl.imt.uni-marburg.de/~rek/aepphage.html>, and in review papers by Cortese, R. et al., (1994) in Trends Biotechn. 12: 262-267., by Clackson, T. & Wells, J.A. (1994) in Trends Biotechn.
 25 12: 173-183, by Marks, J.D. et al., (1992) in J. Biol. Chem. 267: 16007-16010, by Winter, G. et al., (1994) in Annu. Rev. Immunol. 12: 433-455, and by Little, M. et al., (1994) Biotechn. Adv. 12: 539-555. The phages are subsequently used to screen camelid expression libraries expressing camelid heavy chain antibodies. (Muyldermans, S. and Lauwereys, M., Journ. Molec. Recogn. 12: 131-140 (1999) and Ghahroudi, M.A. et al.,
 30 FEBS Letters 414: 512-526 (1997)). Cells from the library that express the desired

antibodies can be replicated and subsequently be used for large scale expression of antibodies.

Examples

Example 1:

Isolation of *Lawsonia intracellularis* from infected porcine ilea.

L. intracellularis infected ilea, confirmed by histopathology and acid-fast Ziehl-Neelsen staining, were collected from pigs died with PE, and stored at -80°C. After thawing *L. intracellularis* bacteria were isolated from mucosal scrapings taken from the infected intestinal wall. The ileal scrapings were homogenized repeatedly in PBS in an omnimixer to release the intracellular bacteria as described by Lawson et al. (Vet. Microbiol. 10: 303-323 (1985)). Supernatant obtained after low-speed centrifugation to remove cell debris was filtered through 5.0, 3.0, 1.2, and 0.8 µm filters (Millipore). The filtrate was subsequently centrifuged at 8000 g for 30 min, giving a small pellet of *L. intracellularis* bacteria. These bacteria were further purified using a Percoll gradient. The identity of the purified bacteria was assessed by PCR (Jones et al., J. Clin. Microbiol. 31: 2611-2615 (1993)) whereas purity of the isolated bacteria (>95%) was assessed by phase contrast microscopy to reveal any contaminating bacteria or gut debris present.

Bacterial strains and plasmids

L. intracellularis cells were isolated from infected ileal material as described above. *Escherichia coli* host strain BL21 star(DE3) containing vector pLysSrare and plasmid pET-His-1 were purchased from Novagen (Madison, Wisconsin, USA). *E. coli* strain TOP10F' was purchased from Invitrogen (Groningen, the Netherlands). Stocks of all bacterial strains, containing 30% glycerol, were stored at -70°C. Luria Bertani broth (LB) and LB plates were prepared according to standard procedures.

25 DNA isolation

In order to obtain highly purified *L. intracellularis* chromosomal DNA, DNA was prepared from bacterial cells using a Biorad chromosomal DNA isolation kit (Biorad, Veenendaal, the Netherlands). Plasmid DNA was isolated using Qiagen products.

30 PCR amplification

PCR amplification was performed using a PCR mixture containing 52 U/ml Expand High Fidelity Enzyme Mix (Roche Applied BioSciences), Expand HF buffer with 2.5 mM MgCl₂, 16 mM dNTPs (Promega, Wisconsin, USA), 20 pmoles of primers and 15 ng chromosomal DNA of *L. intracellularis* as template.

- 5 For standard applications (i.e. colony PCR) the PCR mixture contained 20 U/ml Supertaq and Supertaq buffer (HT Biotechnology Ltd, Cambridge, UK), containing 8 mM dNTPs (Promega, Wisconsin, USA), 10 pmoles of primers and 15 ng template.

Ligation and transformation

- 10 Ligations were performed in a 1 x ligation buffer with 1 unit of ligation enzyme (Gibco BRL Life Technologies Inc., USA) at 16 °C overnight. 1 µl of the ligation reaction was transformed to *E. coli* competent cells by heat shock. The BL21star(DE3) *E. coli* competent cells and the TOP10F' *E. coli* competent cells were made competent using standard methods.

15

Expression of 8xHIS fusion proteins

- The DNA sequence of the expression vector was confirmed by standard sequencing techniques before the expression vector was transformed to BL21star(DE3) containing pLysSrare. The resulting strain was grown overnight at 37°C at 200 rpm in 5 ml LB with
20 100 µg/ml ampicillin. The overnight culture was diluted 1:100 in 50 ml LB with 100 µg/ml ampicillin. This culture was grown under the same conditions until the OD₆₀₀ reached 0.5. The culture was induced with IPTG to a final concentration of 1mM and continued to grow for a subsequent 3 hours. 100 µl samples were taken for analysis. *E. coli* strain BL21star(DE3) containing pLysSrare was grown and induced under the same
25 conditions and samples were taken as a negative control. The samples were analyzed by SDS page.

Polyacrylamide gel electrophoresis and western blotting

- SDS-PAGE was performed using 4-12% Bis-Tris gels from the NuPAGE electrophoresis
30 system (Invitrogen, www.invitrogen.com). Western blotting was performed using semi dry blotting procedures. Western blots were developed using chicken anti-Lawsonia

polyclonal serum that was raised against a whole cell preparation in a water:oil=45:55 emulsion or using a pig serum that had been obtained from a animal that been orally challenged with purified *L. intracellularis* cells and that had developed clinical signs and post-mortem lesions typical for *L. intracellularis* infection. The sera were pre-adsorbed using an equal volume crude cell extracts from BL21star(DE3) containing vector pLysSrare at 4°C for 4 hours.

Results

10 Cloning of *L. intracellularis* gene 5074 in T7 based expression vector

Gene 5074 was amplified using primer 2075 (CATGCCATGGCTAGTCTTACAGCAGGAATGTG) and 2076 (CCGCTCGAGACACGCTTCATATTTACAACTG). In the process a 5' NcoI and 3' XhoI site were introduced into the PCR product. The obtained PCR product was digested using restriction enzymes NcoI and XhoI. The digested PCR product was subsequently ligated to pET22b that had been cut with the same two restriction enzymes. The ligation mixture was transformed to *E. coli* TOP10F and incubated o/n at 37°C. Putative transformants were checked for the right plasmid, using colony PCR. The plasmid inserts, of colony PCR positive transformants, were checked by nucleotide sequence analysis. One of the clones that contained a sequence as expected on basis of the cloning strategy was chosen and designated pET5074.

Expression of *L. intracellularis* gene 5074 from T7 promoter in *E. coli*

Plasmid pET5074 was transformed to BL21 Star(DE3)pLysSrare. The resulting strain was tested for recombinant protein production as described above. Samples of the induced culture and control samples were analysed by SDS-PAGE gel electrophoresis (Fig. 1A). A clear protein band of approximately 75 kDa was observed in sample that had been taken after 3 hours of induction (Fig. 1A, lane 3) in comparison with the uninduced sample (Fig. 1A, lane 2).

30 The same samples were also analysed by western blot using the pig and chicken serum. A reaction with the 75 kD protein was observed using the serum from the pig that had been

orally challenged with purified *L. intracellularis* cells (Fig 1B, lane 3). and with the chicken anti-*L. intracellularis* serum (Fig 1C, lane 3).

Conclusion: the 75 kD vaccine component could be successfully expressed in large
5 quantities and is indeed clearly recognised by both orally challenged pig anti-*L. intracellularis* serum and by chicken anti-*L. intracellularis* serum

Legend to the figure.

Fig. 1. Analysis of the over-expression of *Lawsonia intracellularis* gene 5074 in *Escherichia coli* BL21STAR/pLysSRARE by SDS-PAGE (A) and Western blotting with polyclonal pig serum (B) and polyclonal chicken serum (C). Lane 1, molecular weight marker; lane 2, pET5074 T=0; lane 3, pET5074 T=3. Arrows indicate the location of the expression product.

Claims

- 1) Nucleic acid encoding a 75 kD *Lawsonia intracellularis* protein or a part of said nucleic acid that encodes an immunogenic fragment of said protein, said nucleic acid or said part thereof having at least 90 %, preferably 92 %, more preferably 94 %, even more preferably 96% homology with a nucleic acid having a sequence as depicted in SEQ ID NO: 1
- 2) DNA fragment comprising a nucleic acid according to claim 1.
- 3) Recombinant DNA molecule comprising a nucleic acid according to claim 1 or a DNA fragment according to claim 2, under the control of a functionally linked promoter.
- 4) Live recombinant carrier comprising a nucleic acid according to claim 1, a DNA fragment according to claim 2 or a recombinant DNA molecule according to claim 3.
- 5) Host cell comprising a nucleic acid according to claim 1, a DNA fragment according to claim 2, a recombinant DNA molecule according to claim 3 or a live recombinant carrier according to claim 4.
- 6) A 75 kD *Lawsonia intracellularis* protein, said protein comprising an amino acid sequence that is at least 90 %, preferably 92 %, more preferably 94 %, even more preferably 96 % homologous to the amino acid sequence as depicted in SEQ ID NO: 2, or an immunogenic fragment of said protein.
- 7) *Lawsonia intracellularis* protein according to claim 6 for use in a vaccine.
- 8) Use of a *Lawsonia intracellularis* protein according to claim 6 for the manufacturing of a vaccine for combating *Lawsonia intracellularis* infections.
- 9) Vaccine for combating *Lawsonia intracellularis* infections, characterised in that it comprises a nucleic acid according to claim 1, a DNA fragment according to claim 2, a recombinant DNA molecule according to claim 3, a live recombinant carrier according to claim 4, a host cell according to claim 5 or a protein according to claim 6, and a pharmaceutically acceptable carrier.
- 10) Vaccine according to claim 9, characterised in that it comprises an adjuvant.

- 11) Vaccine according to claim 9 or 10, characterised in that it comprises an additional antigen derived from a virus or micro-organism pathogenic to pigs or genetic information encoding said antigen.
- 5 12) Vaccine according to claim 11, characterised in that said virus or micro-organism pathogenic to pigs is selected from the group of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, *Escherichia coli*, *Erysipelothrix rhusiopathiae*, *Bordetella bronchiseptica*, *Salmonella choleraesuis*, *Haemophilus parasuis*, *Pasteurella multocida*, *Streptococcus suis*, *Mycoplasma hyopneumoniae*, *Brachyspira hyodysenteriae* and *Actinobacillus pleuropneumoniae*.
- 10 13) Vaccine for combating *Lawsonia intracellularis* infections, characterised in that it comprises antibodies against a protein according to claim 6.
- 14) Method for the preparation of a vaccine according to claim 9-13, said method comprising the admixing of a nucleic acid according to claim 1, a DNA fragment
- 15 according to claim 2, a recombinant DNA molecule according to claim 3, a live recombinant carrier according to claim 4, a host cell according to claim 5, a protein according to claim 6, or antibodies against a protein according to claim 6, and a pharmaceutically acceptable carrier.
- 15) Diagnostic test for the detection of antibodies against *Lawsonia intracellularis*,
- 20 characterised in that said test comprises a protein or a fragment thereof as defined in claim 6.
- 16) Diagnostic test for the detection of antigenic material of *Lawsonia intracellularis*, characterised in that said test comprises antibodies against a protein or a fragment thereof as defined in claim 6.

Abstract

The present invention relates i.a. to nucleic acids encoding novel *Lawsonia intracellularis* proteins. It furthermore relates to DNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Also it relates to host cells comprising such nucleic acids, DNA fragments, recombinant DNA molecules and live recombinant carriers. Moreover, the invention relates to proteins encoded by these nucleotide sequences and to their use for the manufacturing of vaccines. The invention also relates to vaccines for combating *Lawsonia intracellularis* infections and methods for the preparation thereof. Finally the invention relates to diagnostic tests for the detection of *Lawsonia intracellularis* antigens and of antibodies against *Lawsonia intracellularis*.




Figure 1.

<110>	AKZO Nobel N.V.	
<120>	Lawsonia intracellularis 75 kD subunit vaccine	
<130>	2004.002	
<160>	2	
<170>	PatentIn version 3.2	
<210>	1	
<211>	2088	
<212>	DNA	
<213>	Lawsonia intracellularis	
<220>		
<221>	CDS	
<222>	(16) .. (2085)	
<400>	1	
cgagggtga ttact atg agt ctt aca gca gga atg tgg aca ggt gtt tca		51
Met Ser Leu Thr Ala Gly Met Trp Thr Gly Val Ser	1 5 10	
gga ctt tta agt cat ggc gaa aag atg aat gtt att ggt aat aac ata		99
Gly Leu Leu Ser His Gly Glu Lys Met Asn Val Ile Gly Asn Asn Ile	15 20 25	
gct aac gta aat aca gta ggc ttt aaa ggc caa cgt atg gat ttc gca		147
Ala Asn Val Asn Thr Val Gly Phe Lys Gly Gln Arg Met Asp Phe Ala	30 35 40	
gac ttt att tat caa gat ggc ttt agt act gca ggg att aca caa att		195
Asp Phe Ile Tyr Gln Asp Gly Phe Ser Thr Ala Gly Ile Thr Gln Ile	45 50 55 60	
gga cgt ggt gta ggc att gga gct gtc atg ggg aac ttt ggt cag ggt		243
Gly Arg Gly Val Gly Ile Gly Ala Val Met Gly Asn Phe Gly Gln Gly	65 70 75	
agt ttt gaa acc aca act gaa gca aca gac ctt gct att ggt ggt cgt		291
Ser Phe Glu Thr Thr Thr Glu Ala Thr Asp Leu Ala Ile Gly Gly Arg	80 85 90	
gga ttt ttc aaa gtt aaa cca caa gga tca gag act tca tat tat acc		339
Gly Phe Phe Lys Val Lys Pro Gln Gly Ser Glu Thr Ser Tyr Tyr Thr	95 100 105	
cgt gca ggt aat ttt cgt ttt aat aat gat gga tac tta gtt gat cct		387
Arg Ala Gly Asn Phe Arg Phe Asn Asn Asp Gly Tyr Leu Val Asp Pro	110 115 120	
cat gga tat gct ctt cag ggt tgg aaa att gat aat act gaa ggg cca		435
His Gly Tyr Ala Leu Gln Gly Trp Lys Ile Asp Asn Thr Glu Gly Pro	125 130 135 140	
caa cgt atc tca ggt ggt gtt aat cca ggt aca aat act tca cag att		483
Gln Arg Ile Ser Gly Gly Val Asn Pro Gly Thr Asn Thr Ser Gln Ile	145 150 155	
atg ggt aca ggt gaa cca aca gat atc cgt ctt gat act tgg aca gtt		531
Met Gly Thr Gly Glu Pro Thr Asp Ile Arg Leu Asp Thr Trp Thr Val	160 165 170	
gca cct tta cag aca aca aat gta agt ttt aac gta aac ctt tct tct		579

Ala Pro Leu Gln Thr Thr Asn Val Ser Phe Asn Val Asn Leu Ser Ser	
175 180 185	
gat aaa tct gga gat aaa tct caa aac gtt aat agt cca ttt acc tca	627
Asp Lys Ser Gly Asp Lys Ser Gln Asn Val Asn Ser Pro Phe Thr Ser	
190 195 200	
tta ttt aat ata tgg aat ggt aaa caa cca agt gaa cct aac aat cca	675
Leu Phe Asn Ile Trp Asn Gly Lys Gln Pro Ser Glu Pro Asn Asn Pro	
205 210 215 220	
cct atg cct gaa agt gca tat agt tat cag aca tct att aag gta tat	723
Pro Met Pro Glu Ser Ala Tyr Ser Tyr Gln Thr Ser Ile Lys Val Tyr	
225 230 235	
gat gaa gct ggt gga aca cat aca tta aca gtc tat ttt gac caa gtt	771
Asp Glu Ala Gly Thr His Thr Leu Thr Val Tyr Phe Asp Gln Val	
240 245 250	
tct cct aaa gac tac aaa ggt ggt gga agt gga gaa agt gta tgg gaa	819
Ser Pro Lys Asp Tyr Lys Gly Gly Ser Gly Glu Ser Val Trp Glu	
255 260 265	
tac gtt gtt act atg gat cct tct gaa gat aat cgc caa gtt tct gtt	867
Tyr Val Val Thr Met Asp Pro Ser Glu Asp Asn Arg Gln Val Ser Val	
270 275 280	
ggt ggt aac att gtg gac atc aaa gat act aaa gct gca gga atg tta	915
Gly Gly Asn Ile Val Asp Ile Lys Asp Thr Lys Ala Ala Gly Met Leu	
285 290 295 300	
atg tca gga aca ttg agt ttt gat agc tca gga aaa ctt gca aac caa	963
Met Ser Gly Thr Leu Ser Phe Asp Ser Ser Gly Lys Leu Ala Asn Gln	
305 310 315	
agt gca tat tgc ctg aat ggt tca cgt aag cct gca gtt gat cct gca	1011
Ser Ala Tyr Ser Leu Asn Gly Ser Arg Lys Pro Ala Val Asp Pro Ala	
320 325 330	
acc gga gct ctt att aat ggt aat ggt ttt act att gat aga gat gga	1059
Thr Gly Ala Leu Ile Asn Gly Asn Gly Phe Thr Ile Asp Arg Asp Gly	
335 340 345	
aat gca att cct att ctt aat ata gat aat cca gct gaa aac ttc tat	1107
Asn Ala Ile Pro Ile Leu Asn Ile Asp Asn Pro Ala Glu Asn Phe Tyr	
350 355 360	
cca gca gaa gtt tct aat aat gga ttt cct atg att gta gct aat ttt	1155
Pro Ala Glu Val Ser Asn Asn Gly Phe Pro Met Ile Val Ala Asn Phe	
365 370 375 380	
act ggt gtc cca ggt aaa aat aca gct gga tct gtt ggt gat gct acc	1203
Thr Gly Val Pro Gly Lys Asn Thr Ala Gly Ser Val Gly Asp Ala Thr	
385 390 395	
acc ttt ttt aca gaa att gac ttt ggt tta aaa gct act gat ctt gat	1251
Thr Phe Phe Thr Glu Ile Asp Phe Gly Leu Lys Ala Thr Asp Leu Asp	
400 405 410	
aat aca tgg aag aat gca aat gaa cct ctt tct tct tta agc tat aaa	1299
Asn Thr Trp Lys Asn Ala Asn Glu Pro Leu Ser Ser Leu Ser Tyr Lys	
415 420 425	
aaa aca cat aat cct atg gat gtc gca ggt ggt tgg aca gtt ggt ggg	1347
Lys Thr His Asn Pro Met Asp Val Ala Gly Gly Trp Thr Val Gly Gly	
430 435 440	
tat aaa act cca gct cca tca gta act gaa ctt ggt atg gct cag ata	1395

Tyr Lys Thr Pro Ala Pro Ser Val Thr Glu Leu Gly Met Ala Gln Ile
 445 450 455 460
 ttg gaa aat cct gct ggg gta atg cca caa tat tat ttt ggt aac cct 1443
 Leu Glu Asn Pro Ala Gly Val Met Pro Gln Tyr Tyr Phe Gly Asn Pro
 465 470 475
 aac tat gat aac aca gtt cca cag agt cca cca tat gta tat aaa aat 1491
 Asn Tyr Asp Thr Val Pro Gln Ser Pro Pro Tyr Val Tyr Lys Asn
 480 485 490
 gaa gct tct tat cag gct gca tat aag act gca tta act gcc gca ggt 1539
 Glu Ala Ser Tyr Gln Ala Ala Tyr Lys Thr Ala Leu Thr Ala Ala Gly
 495 500 505
 ggt acc gca gct gac att aaa aag gaa cat tgg cct cat aat gct gca 1587
 Gly Thr Ala Ala Asp Ile Lys Lys Glu His Trp Pro His Asn Ala Ala
 510 515 520
 tca ggt ata tta gaa gct aat gat cca cca aat gtt aaa gac tta gct 1635
 Ser Gly Ile Leu Glu Ala Asn Asp Pro Pro Asn Val Lys Asp Leu Ala
 525 530 535 540
 aat atg aat gga aca cca aac cgc tta tca aat gcg ttt act aac tat 1683
 Asn Met Asn Gly Thr Pro Asn Arg Leu Ser Asn Ala Phe Thr Asn Tyr
 545 550 555
 gca ggt ggt agc tct aca aaa tct gca agt caa aat ggt tat ggt ttt 1731
 Ala Gly Gly Ser Ser Thr Lys Ser Ala Ser Gln Asn Gly Tyr Gly Phe
 560 565 570
 ggt gat tta atg aac tat agt gta aat gct gag gga gtg tta ttt gga 1779
 Gly Asp Leu Met Asn Tyr Ser Val Asn Ala Glu Gly Val Leu Phe Gly
 575 580 585
 gta tat tca aat gga gta caa ctt cca tta tat caa gta gct ctt tat 1827
 Val Tyr Ser Asn Gly Val Gln Leu Pro Leu Tyr Gln Val Ala Leu Tyr
 590 595 600
 gat ttt aac tct aaa cag ggg tta cgt cgt gaa ggt ggt aac tta ttt 1875
 Asp Phe Asn Ser Lys Gln Gly Leu Arg Arg Glu Gly Gly Asn Leu Phe
 605 610 615 620
 agt caa aca aga gaa tca ggg gac cca tct tca ggt gct gca aac act 1923
 Ser Gln Thr Arg Glu Ser Gly Asp Pro Ser Ser Gly Ala Ala Asn Thr
 625 630 635
 tct ggg ttt ggt tca att aac gct aat act tta gaa gga tca aac gta 1971
 Ser Gly Phe Gly Ser Ile Asn Ala Asn Thr Leu Glu Gly Ser Asn Val
 640 645 650
 gat ata tct aca gag ttt gtc tca atg att gca aca caa cgt gga ttc 2019
 Asp Ile Ser Thr Glu Phe Val Ser Met Ile Ala Thr Gln Arg Gly Phe
 655 660 665
 cag tca aat agt aaa att gta act act att gac caa atg tta gag aca 2067
 Gln Ser Asn Ser Lys Ile Val Thr Thr Ile Asp Gln Met Leu Glu Thr
 670 675 680
 gtt gta aat atg aag cgt tag 2088
 Val Val Asn Met Lys Arg
 685 690

<210> 2
 <211> 690
 <212> PRT
 <213> Lawsonia intracellularis

<400> 2

Met Ser Leu Thr Ala Gly Met Trp Thr Gly Val Ser Gly Leu Leu Ser
 1 5 10 15

His Gly Glu Lys Met Asn Val Ile Gly Asn Asn Ile Ala Asn Val Asn
 20 25 30

Thr Val Gly Phe Lys Gly Gln Arg Met Asp Phe Ala Asp Phe Ile Tyr
 35 40 45

Gln Asp Gly Phe Ser Thr Ala Gly Ile Thr Gln Ile Gly Arg Gly Val
 50 55 60

Gly Ile Gly Ala Val Met Gly Asn Phe Gly Gln Gly Ser Phe Glu Thr
 65 70 75 80

Thr Thr Glu Ala Thr Asp Leu Ala Ile Gly Gly Arg Gly Phe Phe Lys
 85 90 95

Val Lys Pro Gln Gly Ser Glu Thr Ser Tyr Tyr Thr Arg Ala Gly Asn
 100 105 110

Phe Arg Phe Asn Asn Asp Gly Tyr Leu Val Asp Pro His Gly Tyr Ala
 115 120 125

Leu Gln Gly Trp Lys Ile Asp Asn Thr Glu Gly Pro Gln Arg Ile Ser
 130 135 140

Gly Gly Val Asn Pro Gly Thr Asn Thr Ser Gln Ile Met Gly Thr Gly
 145 150 155 160

Glu Pro Thr Asp Ile Arg Leu Asp Thr Trp Thr Val Ala Pro Leu Gln
 165 170 175

Thr Thr Asn Val Ser Phe Asn Val Asn Leu Ser Ser Asp Lys Ser Gly
 180 185 190

Asp Lys Ser Gln Asn Val Asn Ser Pro Phe Thr Ser Leu Phe Asn Ile
 195 200 205

Trp Asn Gly Lys Gln Pro Ser Glu Pro Asn Asn Pro Pro Met Pro Glu
 210 215 220

Ser Ala Tyr Ser Tyr Gln Thr Ser Ile Lys Val Tyr Asp Glu Ala Gly
 225 230 235 240

Gly Thr His Thr Leu Thr Val Tyr Phe Asp Gln Val Ser Pro Lys Asp
 245 250 255

Tyr Lys Gly Gly Gly Ser Gly Glu Ser Val Trp Glu Tyr Val Val Thr

260 265 270
 Met Asp Pro Ser Glu Asp Asn Arg Gln Val Ser Val Gly Gly Asn Ile
 275 280 285
 Val Asp Ile Lys Asp Thr Lys Ala Ala Gly Met Leu Met Ser Gly Thr
 290 295 300
 Leu Ser Phe Asp Ser Ser Gly Lys Leu Ala Asn Gln Ser Ala Tyr Ser
 305 310 315 320
 Leu Asn Gly Ser Arg Lys Pro Ala Val Asp Pro Ala Thr Gly Ala Leu
 325 330 335
 Ile Asn Gly Asn Gly Phe Thr Ile Asp Arg Asp Gly Asn Ala Ile Pro
 340 345 350
 Ile Leu Asn Ile Asp Asn Pro Ala Glu Asn Phe Tyr Pro Ala Glu Val
 355 360 365
 Ser Asn Asn Gly Phe Pro Met Ile Val Ala Asn Phe Thr Gly Val Pro
 370 375 380
 Gly Lys Asn Thr Ala Gly Ser Val Gly Asp Ala Thr Thr Phe Phe Thr
 385 390 395 400
 Glu Ile Asp Phe Gly Leu Lys Ala Thr Asp Leu Asp Asn Thr Trp Lys
 405 410 415
 Asn Ala Asn Glu Pro Leu Ser Ser Leu Ser Tyr Lys Lys Thr His Asn
 420 425 430
 Pro Met Asp Val Ala Gly Gly Trp Thr Val Gly Gly Tyr Lys Thr Pro
 435 440 445
 Ala Pro Ser Val Thr Glu Leu Gly Met Ala Gln Ile Leu Glu Asn Pro
 450 455 460
 Ala Gly Val Met Pro Gln Tyr Tyr Phe Gly Asn Pro Asn Tyr Asp Asn
 465 470 475 480
 Thr Val Pro Gln Ser Pro Pro Tyr Val Tyr Lys Asn Glu Ala Ser Tyr
 485 490 495
 Gln Ala Ala Tyr Lys Thr Ala Leu Thr Ala Ala Gly Gly Thr Ala Ala
 500 505 510
 Asp Ile Lys Lys Glu His Trp Pro His Asn Ala Ala Ser Gly Ile Leu
 515 520 525
 Glu Ala Asn Asp Pro Pro Asn Val Lys Asp Leu Ala Asn Met Asn Gly

530

535

540

Thr Pro Asn Arg Leu Ser Asn Ala Phe Thr Asn Tyr Ala Gly Gly Ser
 545 550 555 560

Ser Thr Lys Ser Ala Ser Gln Asn Gly Tyr Gly Phe Gly Asp Leu Met
 565 570 575

Asn Tyr Ser Val Asn Ala Glu Gly Val Leu Phe Gly Val Tyr Ser Asn
 580 585 590

Gly Val Gln Leu Pro Leu Tyr Gln Val Ala Leu Tyr Asp Phe Asn Ser
 595 600 605

Lys Gln Gly Leu Arg Arg Glu Gly Gly Asn Leu Phe Ser Gln Thr Arg
 610 615 620

Glu Ser Gly Asp Pro Ser Ser Gly Ala Ala Asn Thr Ser Gly Phe Gly
 625 630 635 640

Ser Ile Asn Ala Asn Thr Leu Glu Gly Ser Asn Val Asp Ile Ser Thr
 645 650 655

Glu Phe Val Ser Met Ile Ala Thr Gln Arg Gly Phe Gln Ser Asn Ser
 660 665 670

Lys Ile Val Thr Thr Ile Asp Gln Met Leu Glu Thr Val Val Asn Met
 675 680 685

Lys Arg
 690